ArticleDepression and anxiety2025
Mood Symptoms are Associated With Cognitive Status, Brain Amyloid-Beta Deposition, and Plasma Biomarkers.
Article in Depression and anxiety, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Previous studies have indicated an association between mood symptoms and cognitive decline in the Alzheimer's disease (AD) spectrum. Amyloid-beta (Aβ) deposition in the brain, which is a core pathological characteristic of AD, along with the presence of plasma biomarkers, such as phosphorylated tau protein (p-tau), constitutes an early predictive indicator for AD. We attempted to explore the relationship between mood symptoms and the presence of AD-related plasma biomarkers in patients with brain Aβ deposition. Method: We included 2612 participants aged ≥50 years (707 males; average age 66.98 ± 7.75 years) in this study. We used the Hamilton depression rating scale (HAMD) and Hamilton anxiety rating scale (HAMA) to assess mood symptoms. Cognitive status was categorized into AD, mild cognitive impairment (MCI), subjective cognitive decline (SCD), and normal cognition (NC). We used analysis of covariance (ANCOVA) to compare mood symptoms assessment scores in different cognitive groups after making adjustments for age, gender, and education. Linear regression analysis was used to investigate the association between mood scores and plasma biomarker levels, adjusting for positivity in Aβ PET imaging. Results: Compared to NC patients, patients with AD exhibited higher levels of depression (mean of 4.72 versus 3.39, Conclusion: Plasma biomarkers have significant potential in predicting anxiety and depressive symptoms in individuals with brain Aβ deposition. This can aid the early clinical diagnosis and intervention of AD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.